{
  "extraction_metadata": {
    "timestamp": "2025-09-05T07:31:53.036376",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 6,
    "total_picos": 9
  },
  "picos_by_country": {
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with KRAS G12C and 0-2 performance status and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": "no difference in objective response rate (ORR) and median progression-free survival (mPFS) between patients with KRAS mutation and KRAS wild type, most frequent grade 3 or higher adverse events for sotorasib were diarrhoea, ALT increase, and AST increase"
        },
        {
          "Population": "patients with KRAS G12C and 0-2 performance status and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "no difference in objective response rate (ORR) and median progression-free survival (mPFS) between patients with KRAS mutation and KRAS wild type, most frequent grade 3 or higher adverse events for sotorasib were diarrhoea, ALT increase, and AST increase"
        },
        {
          "Population": "patients with oncogene-driven NSCLC treated with immunotherapy alone",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunotherapy monotherapy",
          "Outcomes": "no difference in objective response rate (ORR) and median progression-free survival (mPFS) between patients with KRAS mutation and KRAS wild type, most frequent grade 3 or higher adverse events for sotorasib were diarrhoea, ALT increase, and AST increase"
        }
      ],
      "ChunksUsed": 16,
      "ContextTokens": 3464
    },
    "NL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with nonâ€“small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression free survival, quality of life, overall survival, objective response rate, adverse events"
        }
      ],
      "ChunksUsed": 9,
      "ContextTokens": 1934
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "symptom control, preservation of quality of life, prolonged survival"
        }
      ],
      "ChunksUsed": 7,
      "ContextTokens": 1539
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation and failure of at least one systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "currently approved (02/22) Sotorasib",
          "Outcomes": "evidence-based recommendation, strong consensus, level 1b evidence"
        }
      ],
      "ChunksUsed": 4,
      "ContextTokens": 692
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "promising results, potential risk of serious side effects on the skin"
        }
      ],
      "ChunksUsed": 14,
      "ContextTokens": 3363
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "increased time before cancer progression, increased overall survival, improved health-related quality of life, objective response rate of 37.1%, potential adverse effects, uncertainty in clinical evidence"
        },
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel plus nintedanib",
          "Outcomes": "increased time before cancer progression, increased overall survival, improved health-related quality of life, objective response rate of 37.1%, potential adverse effects, uncertainty in clinical evidence"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5915
    }
  }
}